• BioVaxys Technology Corp. (BIOV) has expanded its cancer vaccine platform with BVX-0922
  • BioVaxys plans to advance an Investigator-Sponsored Clinical Trial Application (CTA) in the EU with the European Medicines Agency (EMEA) this year
  • Co-founder and Chief Medical Officer Dr. David Berd sat down with Dave Jackson to discuss the news
  • BioVaxys Technology is a clinical-stage biotechnology company that is developing viral and oncology vaccine platforms
  • BioVaxys Technology Corp. (BIOV) opened trading at C$0.15 per share.

BioVaxys Technology Corp. (BIOV) has expanded its cancer vaccine platform with BVX-0922, its autologous haptenized tumor vaccine for colorectal cancer.

BioVaxys plans to advance an Investigator-Sponsored Clinical Trial Application (CTA) in the EU with the European Medicines Agency (EMEA) this year for BVX-0922. An Investigator Sponsored CTA is submitted to regulatory authorities by a clinical investigator who both initiates and conducts an initial clinical study of a new drug or procedure, and under whose immediate direction the investigational drug is administered.

Co-founder and Chief Medical Officer Dr. David Berd sat down with Dave Jackson to discuss the news.

BioVaxys Technology is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.

BioVaxys Technology Corp. (BIOV) opened trading at C$0.15 per share.

More From The Market Online

@ the Bell: Stocks level-out ahead of Easter long weekend

A rebound in oil prices and growth in metal prices helped push Canada’s main stock index higher as investors await economic data.
Bitcoin and cryptocurrency investing concept

U.S. spot Bitcoin ETFs are live – what happens to Canada’s crypto ETFs?

Three since the first spot Bitcoin ETF was introduced in Canada, these funds are finding formidable competition from U.S. counterparts.

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.